Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study.

导出 OA

翻译打印收藏纠错

第一作者： Ilaria,Massa

第一单位： Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy.

作者： Ilaria,Massa ^[1] ; Oriana,Nanni ^[1] ; Massimo,Guidoboni ^[2] ; Giovanni Luca,Frassineti ^[3] ; Andrea,Rocca ^[3] ; Marco Angelo,Burgio ^[3] ; Linda,Valmorri ^[1] ; Mattia,Marri ^[1] ; Alessandra,Piancastelli ^[1] ; Marina,Faedi ^[3] ; Maurizio,Leoni ^[4] ; Stefano,Tamberi ^[5] ; Mattia,Altini ^[6] ; Dino,Amadori ^[3]

作者单位： Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy. ^[1] Immunotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy. ^[2] Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy. ^[3] Oncology Unit, Santa Maria delle Croci Hospital, Ravenna 48121, Italy. ^[4] Oncology Unit, Degli Infermi Hospital, Faenza 48018, Italy. ^[5] Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy. ^[6]

关键词 appropriateness biological drug resource optimisation tumour biomarker

DOI 10.3892/ol.2015.3967

PMID 26870292

发布时间 2023-11-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交